Event Participants
Executives
3 Nitika Dhawan, Samir Kashyap, Sugandha Singhal
Analysts
8 Ankur (Axis Capital), Archit Joshi (Nuvama), Arjun Khanna (Kotak Mahindra), Jesins (IDBI Capital), Naushad Chaudhary (Aditya Birla), Ranjit (IIFL Capital), Rohit Nagraj (360 ONE Capital), Sanjesh Jain (ICICI Securities)
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Gross operating revenue | ₹5,033 crore | Best-ever quarterly performance; driven by chemicals (+26% YoY) and Performance Films (+42% YoY) |
| Chemicals business revenue | ₹2,315 crore | +26% YoY; fluorochemicals strong on refrigerant pricing, healthy domestic demand and robust exports; specialty chemicals showed early volume/price recovery |
| Performance Films & Foils revenue | ₹2,017 crore | +42% YoY; geopolitical supply disruptions allowed full-capacity operations while competitors shut plants; panic buying lifted prices |
| Technical Textiles revenue | ₹597 crore | Stable; NTCF resilient, belting fabrics aided by US demand and tariff rationalization, PIY share gains in geotextiles/seat belts |
| Operational EBIT | ₹1,116 crore | +61% YoY; EBIT margin of 22% |
| Profit after tax | ₹759 crore | +76% YoY |
| Interim dividend | ₹5 per share | Board-approved for Q1 FY27 |
Geographic & Segment Commentary
Chemicals Business (Specialty Chemicals + Fluorochemicals): Revenues of ₹2,315 crore, +26% YoY. Specialty chemicals held market share through the downturn and is now seeing volumes improve for a second consecutive quarter with prices marginally up on key products. Fluorochemicals delivered strong volumes across refrigerants, industrial chemicals, and fluoropolymers; HFC facilities operated at high utilization. Q2/Q3 will be seasonally weaker but strong YoY growth expected.
Performance Films & Foils: Revenues of ₹2,017 crore, +42% YoY. The business operated at ~100% capacity through Middle East disruptions due to globally sourced raw materials; margins improved across all manufacturing locations. Capacitor-grade BOPP film project capitalized under the KAPLAR brand with customer approvals progressing. Aluminum foil exports increased with ~50% of volumes into Europe; aseptic packaging approvals advancing. Q2 expected to normalize to a higher baseline.
Technical Textiles: Revenues of ₹597 crore. Nylon tire cord fabrics stable on resilient end-market demand; belting fabrics benefited from improved domestic demand and robust US exports post tariff rationalization. PIY performed well with improved share in geotextiles and seat belts. Q2 expected to improve YoY.
Other Businesses (Coated & Laminated Fabrics): Stable performance. Coated fabrics maintained domestic leadership with cost discipline and value-added product focus; laminated fabrics benefited from product mix optimization.
Overseas Operations: All overseas locations (including previously pressured Hungary and Ortec) performed well across revenue, EBITDA, and EBIT, underpinning management's view of a higher margin baseline for the films business.
Company-Specific & Strategic Commentary
Odisha Greenfield & Refrigerant Leadership: Strategic investments in next-generation HFO refrigerants, backward integration, and specialty fluoropolymers progressing on plan; post-commissioning, SRF will be among the top 3-4 refrigerant gas manufacturers globally.
Fluoropolymer Scale-Up: PVDF plant commissioning on track for end-Q2 FY27; PTFE value-added grades progressing with small capex on track. Chemours requested design changes requiring European-sourced equipment, delaying FP3/FP4 by ~3-4 months from December timelines. Meaningful fluoropolymer volumes expected from end-FY27/early FY28, full stream by FY28/29.
Capacitor-Grade BOPP Film (KAPLAR): Project capitalized post successful trial runs; offers dielectric stability and self-healing performance. Customer qualification mid-way with approvals secured from several leading customers; early revenue from end-Q2 FY27, near-full capacity by Q1/Q2 FY28. Pricing significantly above vanilla film with limited Indian competition.
BOPET Thick Film Line: Board approved 25,000 MTPA line at ₹250 crore, commissioning in ~24 months. Strategic rationale: enter a new substrate with less price volatility than thin film, expand customer one-stop-shop offering, target electrical/electronics end-use; slated to be India's only dedicated thick-film line.
Aluminum Foil & Aseptic Packaging: Export push gained momentum with ~half of Q1 volumes into Europe; aseptic packaging testing with leading players underway, commercialization expected Q1 FY28 — opening a distinct, higher-priced revenue segment. Jetapur site has ample space for future expansion once higher-grade positioning is secured.
Pharma Ambition: Stated goal of 20-30% of revenue by 2030; working on a growing matrix of molecules × customers, improving the likelihood of commercialization. Volumes currently small but expected to deliver step-function changes when large-scale molecules fructify.
Specialty Chemicals AIs: 6-7 AI molecules in pipeline with peak revenue potential of $400-500 million; capacity and chemistry readiness are in place, with only innovator registrations/launches pending.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Chemicals revenue growth | 15-20% for FY27 (reaffirmed) | Q1 delivered +26%, positioning for the higher end; Q2/Q3 seasonally weaker but YoY growth expected |
| Q2 FY27 performance | Sequentially lower; YoY growth | Seasonal correction from blowout Q1 across chemicals and films; not a demand deterioration |
| Films business margin baseline | Above historical 8-12% EBIT range | Supported by overseas turnaround, value-added mix (capacitor film, metallized/coated), and Europe aluminum exports |
| Refrigerant gas pricing | Sustained through FY27 | Quota-driven tailwinds through December; no China price pressure expected; Q2/Q3 seasonal volume softness in India/Middle East |
| Fluoropolymer contribution | Meaningful from end-FY27/early FY28; full stream FY28/29 | PVDF commissioning end-Q2 FY27, PTFE value grades from Q4 FY27/Q1 FY28, Chemours FP3/FP4 slipped 3-4 months |
| Capacitor-grade BOPP film | Revenue from end-Q2 FY27; near-full capacity by Q1/Q2 FY28 | Customer approvals progressing; strong early acceptance |
| Aseptic packaging (aluminum foil) | Commercialization from Q1 FY28 | Testing with leading players underway |
| BOPET thick film line | Commissioning in ~24 months | ₹250 crore capex; 25,000 MTPA; targets electrical/electronics |
| Pharma revenue share | 20-30% of total revenue by 2030 | Expanding molecule × customer matrix; step-change when large volumes materialize |
Risks & Constraints
| Risk | Context |
|---|---|
| Geopolitical & trade volatility | Middle East conflict and shifting US trade policy drove supply disruptions and panic buying that flattered Q1; management expects Q2 normalization and cannot predict conflict trajectory. US-China duty renewals on refrigerants are a watch item, though management sees no pricing impact through FY27. |
| Raw material cost inflation | Supply-chain disruptions elevated raw material costs in fluorochemicals; improved realizations offset the impact in Q1, but sustained inflation would pressure margins. |
| Specialty chemicals price recovery | China-driven price destruction appears to have bottomed, but recovery is expected to be slow and linear — not a hockey-stick rebound. Price recovery is still in pockets, not broad-based. |
| AI registration timelines | Commercialization of 6-7 AIs ($400-500M peak revenue potential) depends on innovator registration decisions amid pharma economics; management termed timelines "uncertain" with a "last-mile" hurdle. |
| Chemours FP3/FP4 slippage | Design changes requested by Chemours require dedicated European equipment manufacturers, delaying commissioning by 3-4 months from December timelines. |
| Films price correction | Q1's inflated prices from panic buying will correct in Q2; management sees no steep cliff but expects normalization. Crude at ~$70 is supportive of plastics pricing if sustained. |
| Refrigerant seasonality | Q2/Q3 are seasonally weaker for India/Middle East volumes; sequential momentum will temper, though YoY growth is expected to remain strong. |
Q&A Highlights
Specialty Chemicals Recovery & AI Commercialization
- Question: When will the 6-7 AIs scale, and is the base agrochemical business recovering? (Sanjesh Jain, ICICI Securities; Archit Joshi, Nuvama)
- Answer: Volumes improved for a second consecutive quarter and prices are marginally up on key products — the first green shoots, though still in pockets. Recovery will be linear, not hockey-stick, with H2 stronger than H1. Capacity and chemistry for the AIs are ready; only innovator registrations/launches are pending, and timelines remain uncertain. (Samir Kashyap)
Refrigerant Gas Pricing & Middle East Exports
- Question: Are refrigerant prices sustainable, and will US-China duties or Middle East disruptions impact volumes? (Sanjesh Jain; Ranjit, IIFL Capital)
- Answer: Q1 validated the view that pricing would hold or improve; China pricing expected to hold through end-FY27 with no impact from US duty renewals. Q2/Q3 will be seasonally softer but strong YoY. Middle East volumes were robust in Q1 — FLORON receives differentiated pricing there — with strong YoY growth despite Q4 disruption. (Samir Kashyap)
Packaging Films Outperformance & Margin Baseline
- Question: What drove the Q1 outperformance, and is the new baseline above the historical 8-12% margin range? (Jesins, IDBI Capital; Ranjit, IIFL Capital)
- Answer: Competitors shut plants during Middle East disruptions while SRF ran at 100% capacity due to robust global raw material sourcing and DTA operations; panic buying lifted prices. Margins will normalize in Q2, but the baseline will be north of the historical range, driven by overseas improvements (Hungary, Ortec) and value-added products like capacitor film. (Samir Kashyap)
Aluminum Foil Ramp-Up & BOPET/BOPP Outlook
- Question: How fast can aluminum foil reach full utilization, and what is the packaging film price outlook? (Arjun Khanna, Kotak Mahindra; Ankur, Axis Capital)
- Answer: ~50% of Q1 aluminum volumes went to Europe; utilization can reach full capacity if the trend holds. Aseptic packaging commercialization from Q1 FY28. BOPET/BOPP prices will correct from Q1 peaks but no steep cliff if crude holds at ~$70. Expansion of aluminum capacity not under consideration until higher-grade positioning (aseptic) is achieved. (Samir Kashyap)
Fluoropolymers & Chemours Timelines
- Question: When do PTFE, PVDF, and Chemours volumes become meaningful? (Arjun Khanna; Rohit Nagraj, 360 ONE Capital)
- Answer: PVDF commissions end-Q2 FY27; PTFE value-added grades reach meaningful scale by Q4 FY27/Q1 FY28. Chemours-requested design changes requiring European equipment slip FP3/FP4 by 3-4 months. Revenue begins within the first year of commissioning, with full stream in FY28/29 — Chemours is happy with progress. (Samir Kashyap)
Capacitor-Grade Film Economics
- Question: How do capacitor-grade film economics and volatility compare with the base packaging business? (Naushad Chaudhary, Aditya Birla)
- Answer: Pricing is significantly better than vanilla film with lower volatility — a deliberate de-risking strategy from thin-film cyclicality. Customer testing is mid-way; early revenue from end-Q2 FY27, near-full capacity by Q1/Q2 FY28. Few Indian producers, with a growing customer universe. (Samir Kashyap)
Chemicals Growth Drivers & Pharma Trajectory
- Question: What are the key growth drivers for the chemicals business, including pharma? (Jesins)
- Answer: Refrigerants are the standout driver; chemicals growth guidance of 15-20% for FY27 is held with Q1 at +26%, likely landing at the higher end. Pharma share goal remains 20-30% by 2030; expanding molecule × customer matrix improves hit rate, with step-change when large volumes truly scale. (Samir Kashyap)
Dahej Land Availability
- Question: Is there adequate land at Dahej until the Odisha plant comes up? (Sanjesh Jain)
- Answer: Adequate space specifically for specialty chemicals for the next 24 months; all other capex space is already earmarked with work ongoing. (Samir Kashyap)
Key Takeaway
SRF delivered its best-ever quarterly performance in Q1 FY27 with gross revenue of ₹5,033 crore, operational EBIT of ₹1,116 crore (+61% YoY, 22% margin), and PAT of ₹759 crore (+76% YoY). Chemicals grew 26% YoY to ₹2,315 crore on strong refrigerant pricing/volumes and early green shoots in specialty chemicals, while Performance Films surged 42% YoY to ₹2,017 crore, aided by Middle East-driven supply disruptions that let SRF run at full capacity while competitors shut plants. Management reaffirmed 15-20% chemicals growth for FY27 while flagging Q2 seasonality; films will normalize at a higher baseline. Strategy centers on fluoropolymer scale-up (PVDF commissioning end-Q2 FY27, Chemours FP3/FP4 slipped 3-4 months), capacitor-grade BOPP ramp, a ₹250-crore BOPET thick-film line, and aluminum foil export/aseptic push. Watch points: specialty chemical price recovery pace, AI registration timelines, and refrigerant quota-driven tailwinds through December.